NEW YORK (GenomeWeb News) – Mayo Clinic and Mayo Medical Laboratories will offer BioTheranostics' CancerType ID molecular cancer classification test under a deal announced today.

The test is being offered as part of Mayo's surgical pathology consultants to help manage patients with metastatic cancer, and will be made available to Mayo Clinic physicians and patients. Additionally, Mayo Medical Laboratories will offer the test to the more than 5,000 hospitals it serves globally, BioTheranostics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.